Drug maker Genzyme Corp. will pay the Food and Drug Administration $175 million to settle a consent decree, a serious enforcement action.  The FDA issued the consent decree against Genzyme after a series of manufacturing problems led to shortages of two of its drugs, Fabrazyme and Cerezyme. 

In addition to the $175 million payment, the consent decree calls for Genzyme to change the operations site for the end stages of drug production.  It will also develop a remediation plan for the plant in Allston, Mass., subject to approval by the FDA.

According to a statement issued by Genzyme, the company will continue to negotiate with the FDA to finalize the terms of the settlement.

Click here to read the full article, “Genzyme to pay FDA $175m in settlement”